Citations 12
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
Talpaz, Moshe , Stein, Brady L. , Gupta, Vikas , Szőke, Anita , Drummond, Mark W., Pristupa, Alexander , Granston, Tanya, Daly, Robert, Al‐Fayoumi, Suliman , Callahan, Jennifer, Jamieson, Catriona , Harrison, Claire , Verstovšek, Srđan , Mesa, Ruben, Verstovsek, Srdan , Gupta, Vikas , Mascarenhas, John , Hoffman, Ronald , Gerds, Aaron T. , Singer, Jack W. , Gotlib, Jason , Mesa, Ruben A. , Talpaz, Moshe
JAMA Oncology | March 8, 2018 | Volume: 4 | Issue: 5 | Pages: 652
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
Pardanani, Animesh , Harrison, Claire , Cortes, Jörge E. , Cervantes, Francisco , Milligan, Donald, Masszi, Tamás , Mishchenko, Elena, Jourdan, Éric , Drummond, Mark W., Jurgutis, Mindaugas, Kuliczkowski, Kazimierz , Gheorghita, Emanuil, Passamonti, Francesco , Neumann, Frank , Patki, Abhay, Gao, Guozhi, Tefferi, Ayalew , Mesa, Ruben A. , Vannucchi, Alessandro M. , Cortes, Jorge , Passamonti, Francesco , Masszi, Tamas
JAMA Oncology | June 18, 2015 | Volume: 1 | Issue: 5 | Pages: 643